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Abstract 
Background: In 2012 the Artemisinin Monotherapy Therapy Replacement (AMTR) project was implemented in East-
ern Myanmar to increase access to subsidized, quality-assured artemisinin combination therapy (ACT) and to remove 
oral artemisinin monotherapy (AMT) from the private sector. The aim of this paper is to examine changes over time in 
the private sector anti-malarial landscape and to illustrate the value of complementary interventions in the context of 
a national ACT subsidy.
Methods: Three rounds of cross-sectional malaria medicine outlet surveys were conducted, in 2012, 2013 and 2014. 
Project intervention areas were selected from the Myanmar Artemisinin Resistance Containment (MARC) area. Pro-
vider detailing was implemented in these selected areas. Comparison areas were selected outside of this catchment 
area, from townships in close proximity to the MARC framework. Within each domain, multi-staged sampling was 
used to select areas for the survey. Outlets with the potential to sell or distribute anti-malarials in the private sector 
were screened for eligibility.
Results: The total number of outlets approached for an interview was as follows in the intervention and comparison 
areas, respectively: 2012, N = 2046 and 1612; 2013, N = 1636 and 1884; 2014, N = 2939 and 2941. The percentage 
of pharmacies, general retailers and mobile providers (classed as ‘priority outlets’) with oral AMT in stock on the day 
of the survey decreased over time in the intervention areas (2012 = 68 %; 2013 = 48 %; 2014 = 10 %). Conversely, 
quality-assured ACT availability increased among these outlets (2012 = 4 %; 2013 = 62 %; 2014 = 79 %). Relative oral 
AMT market share among priority outlets also decreased over time (2012 = 44 %; 2013 = 18 %; 2014 = 14 %), while 
market share of quality-assured ACT increased (2012 = 3 %; 2013 = 59 %; 2014 = 51 %). Among priority outlets in 
the comparison area, similar trends were observed, though changes over time were less substantial compared to the 
intervention area. Other outlet types (community health workers and health facilities) performed relatively well over 
time though modest improvements were also observed.
Conclusion: The findings point to the successful design and implementation of a strategy to rapidly remove oral 
AMT from pharmacies, general retailers and mobile providers and to replace its use with quality-assured ACT. The 
evidence also highlights the importance of supporting interventions in the context of a high-level subsidy.
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Background
Continued use of oral artemisinin-based monotherapy 
is widely considered to be one of the main contributing 
factors to the development and spread of resistance to 
artemisinin and its derivatives [1]. Since 2006, the World 
Health Organization (WHO) urged countries and phar-
maceutical companies to cease the marketing and use 
of oral artemisinin monotherapy in both the public and 
private sectors [2]. This was of acute concern given evi-
dence of emerging artemisinin resistance in the Greater 
Mekong Sub-region (GMS), which was initially con-
firmed along the Cambodia–Thailand border but is now 
widespread in most of mainland Southeast Asia [3–7], 
including Myanmar [8, 9].
Myanmar is critical to the global containment of resist-
ance; it has a far higher burden of disease than the rest of 
the GMS combined, low levels of investment in malaria 
control and health system strengthening [10, 11], exten-
sive cross-border migration [12], hard-to-reach forested 
areas [13], and high consumption of incomplete doses 
of oral artemisinin monotherapy, namely from the pri-
vate sector [11]. In 2011, the situation in Myanmar was 
particularly challenging given estimates that approxi-
mately 1.3 million adult equivalent treatment doses 
(AETD) of oral artemisinin monotherapy were being 
imported into Myanmar each year in the private sector, 
primarily artesunate tablets [14]. At the same time, sub-
stantial gains had been made in malaria control efforts, 
with reductions in malaria incidence rates attributed 
to increased intervention coverage [11]. For example, 
data from 135 townships found that between 2007 and 
2011 the proportion of fever patients seeking treatment 
from village malaria workers testing positive for malaria 
decreased across all sites from an average of 41 to 24 %, 
respectively [11].
Myanmar’s efforts to ban the production, market-
ing authorization, export, import, and use of oral arte-
misinin monotherapy commenced in 2011 with a ban on 
the importation of artesunate and, in 2012, with  a sub-
sequent ban on the importation of all artemisinin-based 
monotherapy. However, oral artemisinin monotherapy 
could still be distributed and purchased in Myanmar 
while existing stocks were used up. There was also a 
5-year window through which production and import 
licenses agreed upon prior to the ban would remain legal, 
increasing the likelihood that oral artemisinin uptake 
would continue in Myanmar for some time.
Several steps have been taken by the country to help 
contain and prevent the spread of further artemisinin 
resistance. In 2011, the Myanmar Artemisinin Resist-
ance Containment (MARC) project was implemented in 
the eastern part of the country to ensure improved access 
to the country’s first-line artemisinin-based combination 
therapy (ACT) treatment for uncomplicated falciparum 
malaria. While several activities were implemented by in-
country partners and the National Malarial Control Pro-
gram (NMCP), to address the private sector supply-side 
challenges, the Artemisinin Monotherapy Replacement 
Project (AMTR) was implemented by the international 
non-profit organization Population Services Interna-
tional (PSI)/Myanmar  (Fig.  1). The AMTR project was 
designed to rapidly replace the widespread availability 
and use of oral artemisinin monotherapy with subsidized 
quality-assured ACT (ACT that comply with the Global 
Fund to Fight AIDS, Tuberculosis and Malaria’s Quality 
Assurance Policy). Efforts targeted distribution and sales 
in the private sector [15] given evidence that an estimated 
50–80 % of people in Myanmar seek treatment from this 
sector [16].
The national scale of the AMTR project and its ability 
to shape the anti-malarial market in Myanmar could be 
a key asset in national efforts to delay artemisinin resist-
ance and move toward the pre-elimination phase of 
malaria elimination in accordance with the GMS Malaria 
Elimination Plan [17]. Understanding the potential 
impact of the AMTR intervention will help to examine 
the importance of a high-level subsidy for quality-assured 
ACT as well as the role of other supporting interventions. 
Fig. 1 Map of AMTR project areas
Page 4 of 13Khin et al. Malar J  (2016) 15:286 
The main aim of this paper is to show changes over time 
in the private sector anti-malarial landscape as a result of 
the AMTR project in eastern Myanmar between 2012, 
2013 and 2014. A secondary objective is to illustrate the 
role of supportive provider interventions focused on pri-
ority outlets in targeted areas in eastern Myanmar as a 
means to illustrate the value of complementary interven-
tions in the context of a national ACT subsidy and efforts 
to remove oral artemisinin monotherapy from the private 
sector market.
Methods
The methodology for the project was adapted from 
the ACTwatch project [18]. The ACTwatch project is 
a multi-country research project implemented by PSI 
and launched in 2008. The goal of the ACTwatch pro-
ject is to provide timely, relevant and high-quality anti-
malarial market evidence to inform and monitor national 
and global policy, strategy and funding decisions for 
improving malaria case management. Since the project’s 
inception, standardized tools and approaches have been 
employed to provide comparable data across countries 
and over survey rounds. These approaches have been 
documented elsewhere in detail [18–22].
Description of the interventions
A core component of the AMTR project intervention was 
the national distribution of subsidized quality-assured 
ACT [23]. Supply chain research identified the larg-
est market-sharing company importing artesunate into 
Myanmar (AA Pharmacy), with 70 % of oral artemisinin 
monotherapy distributed by this importer [24]. Negotia-
tions between PSI and AA Pharmacy led to an agreement 
to stop importing the product in late 2011 and to instead 
distribute subsidized, quality-assured ACT sold to end 
users at 500 Kyat (or around $0.75 in 2012). The quality-
assured ACT (artemether–lumefantrine) was branded 
Supa Arte ® and over-packaged by PSI. The packaging 
included a quality-assurance lotus leaf logo for consumer 
recognition of the brand as a high-quality WHO and 
nationally recommended medicine.
The AMTR project also implemented a series of behav-
ior change communication activities to promote the use 
of quality-assured ACT among consumers, using mass 
media activities. The overall objective of these activities 
was to increase demand for the national first-line ACT, 
which could be recognized by patients from the ‘quality 
seal’. ACT sales and mass media were further reinforced 
in the target area by intensive pharmaceutical detailing 
operations targeting priority outlet types through PSI 
product promoters as a means to amplify increases in 
ACT uptake in the supply chain. This supportive inter-
vention specifically targeted three types of informal 
private providers in the intervention areas: pharmacies, 
general retailers, and mobile providers (termed ‘priority 
outlets’). These providers were chosen because the 2012 
outlet survey showed that these types of providers were 
commonly stocking and distributing oral artemisinin 
monotherapy [23] and were generally underserved, with 
little or no ties to the government or non-governmental 
organizations (NGOs) for training, supervision or access 
to quality-assured commodities. The product promot-
ers provided key messaging to providers as well as job 
aids and other awareness-raising tools regarding malaria 
case management. The product promoters did not sell 
ACT directly to the priority outlets but established links 
between the outlets and wholesalers supplying the qual-
ity-assured ACT. To ensure an affordable price for con-
sumers, promoters emphasized a recommended retail 
price for the quality-assured ACT. Priority outlets were 
followed up with  every 3  months by the PSI product 
promoters.
Priority outlets and non-priority outlets in both 
domains received distributions of subsidized ACT and 
were subject to the ban on oral artemisinin monotherapy 
as well as behavior change communication through mass 
media.
Design and sampling
Three rounds of cross-sectional malaria medicine out-
let surveys were conducted in eastern Myanmar, in 2012 
(March–May), 2013 (August–October), and 2014 (Sep-
tember–October). Data collection coincided with the 
Myanmar rainy season when malaria transmission is 
highest, generally beginning in late June and ending in 
December [11].
Each survey was stratified to deliver separate estimates 
for two areas: the ‘intervention’ area, which received 
additional product promotion through medical detailing 
from PSI, and the ‘comparison’ area (areas for which this 
supportive intervention was not implemented). Interven-
tion areas were defined as being located in the MARC 
project area and selected from this project area. The 
comparison area was defined as locations in close prox-
imity to the Myanmar Artemisinin Resistance Contain-
ment (MARC) framework. There was no randomization 
of the intervention and comparison areas as the MARC 
area was pre-defined as a priority area for containment 
activities given artemisinin drug resistance risk.
The study was powered to detect a minimum of a 
15 % point change in availability of quality-assured ACT 
between the two strata (intervention and comparison) 
at each survey round. Based on the desired number of 
anti-malarial stocking outlets within each round and 
assumptions about the number of anti-malarial stocking 
outlets per township, a sample of townships was selected 
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within each research domain with probability propor-
tional to population size, using a multi-staged cluster 
sampling approach. Within each selected urban ward or 
rural village tract (administrative boundaries in Myan-
mar), all private sector outlets with the potential to pro-
vide anti-malarials to patients were sampled (see Table 1 
for a description of the outlet types). Further details of 
the sample size assumptions and sample selection are 
described elsewhere [25]. A census approach was used to 
identify outlets. Outlets were eligible for a provider inter-
view and malaria product audit if they met at least one of 
the study criteria: (1) one or more anti-malarials report-
edly in stock the day of the survey; and, (2) one or more 
anti-malarials reportedly in stock within the 3  months 
preceding the survey.
Training and fieldwork
For all survey rounds, interviewer training was provided 
over a minimum of six days using standardized training 
materials. The training focused on outlet identification, 
informed consent procedures and procedures for com-
pleting the questionnaire. An additional file shows the 
full outlet survey questionnaire (see Additional file 1). An 
additional two-day training was provided for quality con-
trollers and supervisors.
Field workers were provided with a list of the selected 
administrative areas, maps that illustrated the adminis-
trative boundaries, and any existing official lists of facili-
ties. Snowball sampling was used by field workers to 
identify facilities that were not on official lists. In each 
selected cluster, field workers conducted a census of all 
outlets that had the potential to provide anti-malarials by 
traveling systematically throughout the selected area. For 
each outlet that was identified during the census, a field 
worker then approached the outlet’s main provider or 
owner, invited him or her to participate in the study and 
screened for eligibility. An interview with a staff member 
who was most likely to sell or prescribe medications was 
conducted. The interview was carried out in Burmese.
During data collection, approximately 80 % of all ques-
tionnaires were reviewed by the team supervisor and 
15–20 % of all outlets were revisited by a supervisor or/
and quality controller for quality control checks.
The core component of the outlet survey is an exhaus-
tive audit of all anti-malarials in stock at the time of the 
survey. The audit collected product information, includ-
ing formulation, brand name, active ingredients and 
strengths, manufacturer, and country of manufacture. 
The audit additionally collected provider reports on 
unit cost and amount distributed to individual patients 
in the previous week. Basic outlet and provider charac-
teristics were collected, including availability of malaria 
microscopy.
Ethical approval
The studies were approved by PSI Research Ethical Board 
(REB) registered under the Office of Human Research 
Protections (OHRP FWA00009154, IRB#00006978). 
Local approval was not obtained due to time sensitivities 
regarding project implementation.
Data analysis
Data collection was paper-based and entered using 
CSPro. Double data entry was conducted using Microsoft 
Access (Microsoft Corp, Redmond, Washington, USA) 
with built-in range and consistency checks. Data were 
analyzed across survey rounds using Stata (StataCorp, 
College Station, TX, USA).
Stata survey settings were used to account for the 
stratified and clustered sampling strategy. Results were 
adjusted by sampling weights. Sampling weights were 
calculated as the inverse of the probability of township 
selection. Standard indicators were constructed accord-
ing to definitions applied across the ACTwatch project 
Table 1 Description of outlet types and classification
Priority outlets
Pharmacies Pharmacies are licensed by the Ministry of Health and are authorized to sell all classes of medicines including prescrip-
tion-only medicines
General retailers General retailers are grocery stores and village shops that sell fast-moving consumer goods, food and provisions. 
Although retailers may have over-the-counter medicines including anti-malarials available, national authorities do not 
regulate the sale of medicines by retailers
Mobile providers Mobile providers selling medicines and other goods. They are not registered with any national regulatory authority
Non-priority outlets
Private health facilities Private general practitioners providing patient services within privately owned facilities that are licensed by the Ministry of 
Health. These practitioners may have formal or informal ties with government health facilities including serving on staff 
at government facilities and/or accessing government or non-government not-for-profit medicine supplies
Community health workers Community-based health workers provide patient services and typically are linked with the government or NGOs, or 
other private health facilities and medical supply agents
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countries and have been described elsewhere [18, 20]. 
Briefly, anti-malarials identified during the outlet drug 
audit were classified according to information on drug 
formulation, contents and strengths with supporting 
information including brand or generic name and manu-
facturer. Among outlets stocking anti-malarials, variables 
were created to indicate availability by type, including 
the broad category of ACT, as well as specific categories 
including: (1) quality-assured ACT (ACT that comply 
with the Global Fund to Fight AIDS, Tuberculosis and 
Malaria’s Quality Assurance Policy), non-quality assured 
ACT, oral artemisinin monotherapy, non-oral artemisinin 
monotherapy, and non-artemisinin monotherapy.
The volume of anti-malarials recorded in the drug 
audit were standardized using an adult equivalent treat-
ment dose (AETD) to allow for meaningful comparisons 
between anti-malarials with different treatment courses. 
Provider reports on the amount of the drug sold or dis-
tributed during the week preceding the survey were used 
to calculate volumes according to type of anti-malarial. 
Measures of volume include all dosage forms to provide 
a complete assessment of anti-malarial market shares. To 
monitor the extent to which the quality-assured ACT was 
sold to patients for the recommended 500 Kyat, an indi-
cator was used to capture the percentage of priority out-
lets that reportedly sold the subsidized ACT at a price less 
than or equal to 500 Kyat. This price was based on con-
sumer perceptions regarding affordability of anti-malarial 
treatments and mark-up along the supply chain [14].
Results
Across the survey rounds the total number of out-
lets approached for an  interview was as follows in the 
intervention and comparison areas, respectively: 2012, 
N = 2046 and N = 1612; 2013, N = 1636 and N = 1884; 
2014, N =  2939 and N =  2941.  Of these, over 95  % of 
outlets were screened for stocking anti-malarials across 
the three survey rounds. The total number of anti-malar-
ials audited during each survey was as follows: 2012, 
N = 3206; 2013, N = 2636; 2014, N = 2396.
Availability
Figure  2 shows the availability of oral artemisinin mon-
otherapy among anti-malarial stocking outlet catego-
ries in the intervention and comparison areas. The 2012 
outlet survey results show that certain outlet types had 
relatively high availability of oral artemisinin monother-
apy  (see Fig.  2), and low availability of quality-assured 
ACT (see Fig. 3), including pharmacies, general retailers 
and mobile providers. These were categorized as ‘priority 
outlets’ and targeted for the product promoter interven-
tion. In contrast, private health facilities and commu-
nity-based health workers had low availability of oral 
artemisinin monotherapy (<30 %) (see Fig. 2), and higher 
availability of quality-assured ACT (see Fig.  3). These 
were categorized as non-priority outlets for the project 
intervention.
The percentage of priority outlets with oral artemisinin 
monotherapy in stock on the day of the survey decreased 
over time in the intervention area from 70  % in 2012 
to 10.3  % in 2014. Oral artemisinin monotherapy also 
declined over time in the comparison area but was less 
remarkable, with 35.1 % stocking this anti-malarial class 
in 2014 compared to 63.7  % in 2012. Data trends sug-
gest declining availability of oral artemisinin monother-
apy over time among non-priority outlets across both 
domains at less than 10 % in 2014.
Figure  3 shows the percentage of outlet categories 
with at least one quality-assured ACT in stock on the 
day of the survey, among anti-malarial stocking outlets. 
Quality-assured ACT availability increased among pri-
ority outlets (pharmacies, general retailers and mobile 
providers) between 2012 (4.2  %)  and 2013 (61.7  %), 
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Fig. 2 Outlets stocking oral artemisinin monotherapy on the day of survey, 2012, 2013, 2014
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of quality-assured ACT among priority outlets was 
similar in 2012 across both domains, only one in three 
priority outlets in the comparison area stocked quality-
assured ACT in 2014 (2012  =  7.4  %; 2013  =  18.0  %; 
2014 = 31.5 %).
Regarding trend data among non-priority outlets, qual-
ity-assured ACT availability among anti-malarial stock-
ing outlet types was generally high and stable over time, 
and availability ranged between ~70 and ~80 % in 2014.
Anti-malarial market share
Figure  4 shows the market share of different categories 
of anti-malarials sold or distributed in the seven days 
prior to the survey over time according to priority outlets 
in the intervention and comparison areas. In 2012, oral 
artemisinin monotherapy accounted for more than 40 % 
of the anti-malarials distributed by priority outlet types 
across both domains.
Among priority outlets from the intervention area, 
oral artemisinin monotherapy (AMT)  market share 
decreased  from 44  % in 2012  to 18  % of the total mar-
ket share in 2013 and 14  % in 2014. Market share of 
quality-assured (QA)  ACT among these priority outlets 
increased from 3 % in 2012 to 51 % in 2014. Most of the 
quality-assured ACT that was sold or distributed in 2013 
and 2014 across both domains had the lotus leaf logo. 
Non-artemisinin therapy (mostly chloroquine) accounted 
for almost one-third of the market share in 2014 among 
priority outlets in the intervention area, reflecting a 
decline from 2012 when it held 44 % of the market share.
Among priority outlets in the comparison area, mar-
ket share of oral artemisinin monotherapy remained 
high over time, although overall declines were noted 
(46  %, 2012; 41  %, 2013; 35  %, 2014). Market share of 
quality-assured ACT was around 30  % in 2013 and 
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Fig. 4 Priority outlet sector market share, by strata
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anti-malarials sold or distributed were non-artemisinin 
monotherapy.
Non-Priority outlet sector market share by strata
In the intervention area among non-priority outlets, 
oral artemisinin monotherapy accounted for 21  % of 
the total anti-malarial market share in 2012 and 9 % in 
2014 (Fig. 5). Increases in quality-assured ACT market 
share were observed from 40 % in 2012 to over 50 % in 
2014.
In the comparison area among non-priority outlets, 
oral artemisinin monotherapy accounted for 10  % of 
the total anti-malarial market share in 2012 and was 
reportedly no longer sold/distributed in 2014. Qual-
ity-assured ACT market share was similar in 2012 and 
2014 and ranged between 60–70 % of the total market 
share.
Relative market share across priority and non-priority 
outlet types and categories
Figures  6, 7 present the relative anti-malarial market 
share of all anti-malarials, regardless of anti-malarial 
class, across each outlet type in 2014. In 2014, the prior-
ity outlets accounted for nearly 90 % of all anti-malarials 
distributed in the comparison areas and nearly 60  % of 
anti-malarials distributed in the intervention  areas, and 
anti-malarial distribution was greatest among pharma-
cies and mobile providers. 
Affordability
The anticipated end users’ price for the PSI-branded, 
quality-assured ACT was set at 500 Kyat (around $0.75 
at the time of the 2012 study). Figure  8 shows the per-
centage of outlets that distributed the subsidized quality-
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Fig. 6 Relative anti-malarial market share in the comparison area, 2014
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that the majority of priority-sector anti-malarial stock-
ing outlets reportedly sold this subsidized anti-malarial 
medicine according to the recommended retail price. 
The results also show that among non-priority outlets, in 
2014 most outlets also conformed to the recommended 
selling price.
Discussion
The AMTR project to address the removal of oral arte-
misinin monotherapy from the market has largely been 
successful as evidenced by substantial reductions in avail-
ability and distribution of oral artemisinin monotherapy 
and increases in availability and distribution of afford-
able, quality-assured ACT in eastern Myanmar. Data 
from three outlet surveys confirm substantial improve-
ments between 2012, 2013 and 2014 regarding removal 
of oral artemisinin monotherapy from the private sector 
and ensuring high availability, market share and afford-
ability of first-line ACT treatments in eastern Myanmar. 
These improvements were most notable among priority 
outlet types, including pharmacies, general retailers and 
mobile providers. The striking improvements among pri-
ority outlet types in intervention areas provide evidence 
on the importance of supportive interventions in the 
context of a high-level subsidy. The data also illustrate the 
importance of priority outlet types as treatment sources 
for febrile patients in Myanmar, given that  most anti-
malarials are being sold or distributed through these out-
let types in the private sector. Despite successful changes 
over time, the findings point to the need for further 
improvements as well as sustained provider and con-
sumer behavior change interventions to ensure optimal 
access to affordable, quality-assured ACT. The following 
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Fig. 8 Distribution of Supa Arte ® for less than 500 Kyat in 2013 and 2014
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Anti-malarial availability and market share among priority 
outlet types
In 2012, the priority outlet types across both the inter-
vention and the comparison areas were poorly per-
forming, with high availability and market share of oral 
artemisinin monotherapy and negligible availability of 
quality-assured ACT. The lack of adherence to national 
malaria guidelines by providers operating in these out-
lets may be attributed to their lack of formal training and 
oversight [20]. Information from this baseline assessment 
provided a key insight regarding the types of outlets that 
needed additional supportive interventions and that were 
subsequently targeted as part of the AMTR project.
In 2013 and 2014, two  years after the project imple-
mentation, substantial increases in the availability of 
quality-assured ACT and improvements in market share 
were observed among priority outlet types, particularly 
in the intervention area. Key improvements observed 
among anti-malarial stocking pharmacies, general 
retailers and mobile providers in the intervention area 
included: (1) dramatic increases in quality-assured ACT 
availability from less than  10  % in 2012 to nearly  80  % 
in 2014; (2) increases in market share of quality-assured 
ACT from less than 5  % in 2012 to over 50  % in 2014, 
reflecting improvements in ACT availability; (3) declines 
in the availability of oral artemisinin monotherapy from 
over 60  % of anti-malarial stocking outlets in 2012 to 
around 10 % in 2014; and, (4) declines in the market share 
of oral artemisinin monotherapy from over 40 % in 2012 
to 14  % in 2014. While similar trends are observed for 
priority outlet types in the comparison group, improve-
ments were limited and suggest that simply targeting 
the supply side through a national subsidy may not be 
enough to ensure sufficient shifts in anti-malarial mar-
kets as a means to achieve adequate coverage and uptake 
of quality-assured ACT.
The relevance of supportive interventions has been 
documented elsewhere, namely through the Afford-
able Medicines Facility for Malaria, implemented in sub-
Saharan Africa, which found that private sector subsidies 
combined with supporting interventions can be effective 
in rapidly improving availability, price and market share 
of quality-assured ACT [26], particularly in the private 
for-profit sector. A core conclusion was that in addition 
to the availability and distribution of a subsidized ACT, 
there is an important role for supporting interventions to 
ensure the success of subsidy programs for public health 
commodities [27]. The notable market improvements 
among pharmacies, general retailers and mobile provid-
ers in the intervention area suggests the added value of a 
product promotion intervention, a finding also supported 
by others [28–30].
Market share of chloroquine hovers around 20  % in 
the intervention area. This could be explained by the 
fact that around 26  % of malaria cases in Myanmar are 
confirmed as vivax malaria [1]. National guidelines stipu-
late that confirmed vivax malaria cases should be treated 
with a full course of chloroquine followed by 14 days of 
primaquine to prevent relapse [1]. It is plausible that the 
market share of chloroquine is in fact reflective of the 
readiness of the market to treat vivax cases (although a 
notable absence of primaquine is recognized). However, 
in the absence of information on the number of con-
firmed malaria diagnostic cases, this is difficult to con-
firm. In addition, while oral artemisinin monotherapy 
market share has declined, in intervention areas this 
appears to have been displaced by a rise in non-oral 
artemisinin monotherapy (which can also increase arte-
misinin resistance, albeit with lower risk). While non-
oral artemisinin monotherapy is for use in severe malaria 
cases, this situation should continue to be monitored 
given the inability of the priority outlet providers to ade-
quately test for and treat severe malaria.
While a number of achievements are seen among the 
priority outlet types, oral artemisinin monotherapy is still 
commonly sold and accounts for up to 35 % of the market 
share in the comparison area. While Myanmar has taken 
regulatory measures to halt the use of oral artemisinin 
monotherapy, the manufacturing and marketing of these 
products is still ongoing (and many of these companies 
are located in China and Vietnam). Persistent sale and 
distribution of oral artemisinin monotherapy may be 
explained by the fact that the importation of licensed oral 
artemisinin monotherapy (products that received a five-
year license prior to implementation of the ban) is still 
permitted as a means to honor existing agreements with 
companies and manufacturers of this drug. National 
efforts should be made to enforce the ban on oral arte-
misinin monotherapy so that this national policy of pub-
lic health significance is followed.
The importance of priority outlet types as a source of care
In the context of the findings on availability and mar-
ket share, it is important to consider the relevance of 
the priority and non-priority outlet types as a source of 
anti-malarial care according to the intervention and com-
parison areas. In 2014, priority outlet types, including 
pharmacies, general retailers and mobile providers, were 
responsible for almost 90 % of private sector anti-malar-
ial drug distribution in comparison areas and almost 60 % 
in the intervention areas. The high relative market share 
for pharmacies, general retailers and mobile providers 
indicates the importance of these outlet types as a source 
of treatment for febrile patients. This finding is further 
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supported by household surveys which have found that 
most people in Myanmar seek treatment in the private 
sector, and most likely from general retailers, mobile pro-
viders and pharmacies [19, 31], indicating the relevance 
of these outlet types as a source of treatment, in addition 
to community health workers and health facilities.
Anti-malarial availability and market share 
among non-priority outlet types
The levels of ACT availability among non-priority outlets 
remained relatively high and stable over time, and market 
share data illustrate that ACT was the most commonly 
distributed anti-malarial, although slight declines were 
observed between 2013 and 2014 in both the interven-
tion and comparison area. Incremental increases were 
also observed regarding the market share of ACT with 
the logo, and in 2014 ACT with the logo comprised about 
30 % of market share in the intervention area and 20 % 
in the comparison area. While these improvements are 
only moderate, it is suggestive of market penetration and 
uptake of subsidized ACT, particularly in the interven-
tion area. While availability of oral artemisinin mono-
therapy was relatively low at baseline, general declines 
were also observed among these outlets so that by 2014, 
less than 10 % had oral artemisinin monotherapy in stock 
on the day of survey.
The performance of the non-priority outlets is quite 
consistent with evidence from other countries which 
illustrates that regulated  outlets (such as private facili-
ties) generally perform better than other private sector 
outlet types [19, 21]. Indeed, in Myanmar several sup-
portive measures have been made to reach these out-
let types and providers through government and other 
NGO efforts, where private health facility providers are 
trained in accordance with national policies and operate 
in specific sites and locations designed by the Govern-
ment of Myanmar [11]. The findings from 2014 indicate 
widespread market share of quality-assured ACT as well 
as distribution and sales of treatment for vivax malaria, 
particularly in the comparison areas, suggesting the read-
iness of the priority outlets to provide malaria treatment 
according to national guidelines.
Price
A key premise of the AMTR project was that promot-
ing maximum coverage of quality-assured ACT in the 
private sector would lead to market competition among 
outlets and help to control the price paid by consumers. 
The anticipated retail price of the quality-assured ACT 
was 500 Kyat. The findings show that most of the prior-
ity and non-priority outlets stocking the quality-assured 
ACT have adhered to this guideline. Higher availability 
and market share of quality-assured ACT over time and 
reductions in oral artemisinin monotherapy thus sup-
ports the initial premise of the AMTR project in ensur-
ing subsidized, quality-assured ACT in the supply chain 
would effectively squeeze out oral artemisinin mono-
therapy due to price competition. This is attributed to 
a multi-pronged approach, including the efficiency of 
private sector supply chain, high coverage and availabil-
ity of quality-assured ACT, and constant supply, as well 
as high-level donor subsidy. Similar findings have been 
found in other countries with relatively high rates of oral 
artemisinin market share, namely Cambodia and Nigeria, 
where the introduction of subsidized ACT in the market 
complemented by other supporting interventions, led to 
increases in quality-assured ACT and declines in oral 
artemisinin monotherapy [26, 31].
Future activities and research
Given declining malaria prevalence rates, as well as the 
confirmation of the spread of artemisinin resistance 
along the western border of Myanmar, the deployment of 
rapid diagnostic tests (RDT) in the private sector would 
now be beneficial to avoid drug wastage, to improve case 
management and to prevent development of resistance to 
partner drugs. An evaluation of the quality of the drugs, 
specifically the quality-assured ACT, that are available 
in the market should also be conducted as a means to 
ensure that no falsified medicines are in circulation, given 
that  sub-standard or fake ACT are a threat to malaria 
elimination and will lead to drug resistance.
Limitations
This study had several limitations, some which are 
inherent to the ACTwatch outlet surveys and have been 
documented elsewhere [20, 21]. Specific to the design 
of this research serving as an evaluation of the AMTR 
project, there was a lack of randomization for interven-
tion and comparison areas. The lack of a randomized 
control group constrains the ability to assess precisely 
the degree to which the changes in availability, price and 
market share are attributable to the AMTR project or 
to the specific provider behavior change strategies that 
were implemented in the intervention areas through the 
product promoters. Documentation of other interven-
tions identified a range of factors that could also have 
improved outcomes, including policy changes banning 
importation and distribution of oral artemisinin mono-
therapy in 2012. Other activities that could have contrib-
uted to change include other supporting interventions 
implemented by partners. As such, caution is merited in 
making causal inferences about the impact of the AMTR 
project and the changes. Finally, the outlet survey reports 
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on relative volumes distributed in terms of full course 
treatments (i.e., AETD). While declining volumes of 
oral artemisinin monotherapy relative to quality-assured 
ACT are observed, it is acknowledged that people may 
receive doses of this drug class that are not full course 
adult treatments. It is therefore plausible that many more 
people will be receiving small doses of oral artemisinin 
monotherapy, which is not well reflected in market share.
Key lessons
There are a number of important lessons that can be taken 
from the AMTR project. In terms of speed, the project 
demonstrated significant improvements in the anti-malar-
ial market landscape in a relatively short period of time. 
This was essential in order to deal with the rapidly chang-
ing epidemiology and fears of further spread of artemisinin 
resistance in 2012. In addition, the project addressed this 
at scale to ensure that quality-assured ACT was made 
available throughout the country and not just confined 
to the eastern border. Utilizing the existing private sector 
supply system rather than creating a parallel system was an 
integral component of this, and, without it, it is doubtful 
whether the project would have been successful in a coun-
try such as Myanmar, where there are more than 130 eth-
nic groups, ethnic conflicts and civil unrest.
Conclusion
In 2012, the widespread availability and use of oral arte-
misinin monotherapy in Myanmar posed a significant 
threat to malaria elimination efforts in the region. Evi-
dence from outlet surveys demonstrated the success-
ful design and implementation of a strategy to rapidly 
remove oral artemisinin monotherapy from pharmacies, 
general retailers and mobile providers and to replace its 
use with quality-assured ACT. It demonstrated the criti-
cal role of the private sector as a source of treatment in 
Myanmar. To this end, the NMCP must continue to 
engage with and monitor the private sector as a means 
to ensure elimination goals are met and treatments are 
administered according to national policy. In line with 
recent epidemiological evidence, the next steps for the 
AMTR project are to focus on rational drug use and 
appropriate treatment for falciparum and vivax malaria 
by increasing access to affordable RDT.
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